Active substance
Results for the substance ocrelizumab
3 results
About this active substance
Ocrelizumab is an alternative name for ocrelizumab, a monoclonal antibody used in the treatment of primary progressive multiple sclerosis and relapsing multiple sclerosis. It works by targeting CD20-positive B lymphocytes, reducing inflammation and disease progression.
The medication is administered intravenously, as directed by a doctor, usually once every six months. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.
Patients should be aware of potential side effects, such as infusion reactions, infections, or fatigue. It is important to inform the doctor of any unusual symptoms.
Common side effects include infusion reactions, infections, and fatigue. In rare cases, severe reactions such as serious infections or allergic reactions may occur. Patients should be informed of these risks before use.
The medication is administered intravenously, as directed by a doctor, usually once every six months. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.
Patients should be aware of potential side effects, such as infusion reactions, infections, or fatigue. It is important to inform the doctor of any unusual symptoms.
Common side effects include infusion reactions, infections, and fatigue. In rare cases, severe reactions such as serious infections or allergic reactions may occur. Patients should be informed of these risks before use.
-
-
OCREVUS 300mg 30mg/ml concentrate for solution for infusion EGIS ORIGINAL MEDICINE
-
OCREVUS 300mg concentrate for solution for infusion EGIS ORIGINAL MEDICINE